Adagene 관리

관리 기준 확인 2/4

Adagene CEO는 Peizhi Luo, Nov2011 에 임명되었습니다 의 임기는 6.75 년입니다. 는 $ 3.27M 가치에 해당하는 회사 주식의 3.25% 직접 소유합니다. 3.27M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 3 년입니다.

주요 정보

Peizhi Luo

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	13yrs
CEO 소유권	3.3%
경영진 평균 재임 기간	6.1yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

CEO

Peizhi Luo (58 yo)

13yrs

테뉴어

Dr. Peter P. Luo, PhD, also known as Peizhi, is the Founder of Adagene Inc. and serves as its Chief Executive Officer since November 2011 and Director since February 2018. He serves as President of R&D at...

리더십 팀

이름	위치	테뉴어	보상	소유권
Peter P. Luo	Co- Founder	13yrs	데이터 없음	3.25% $ 3.3m
Man Kin Tam	CFO & Director	5.2yrs	데이터 없음	데이터 없음
Jc Xu	Chief Scientific Officer	4.3yrs	데이터 없음	데이터 없음
Ami Knoefler	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Ling Zhou	Head of Human Resources	5.1yrs	데이터 없음	데이터 없음
Qinghai Zhao	Chief Manufacturing Officer	4.1yrs	데이터 없음	데이터 없음
Yan Li	Senior Vice President of Bioinformatics & Information Technology	13yrs	데이터 없음	데이터 없음
Xiaohong She	Senior VP & Head of Clinical Operations	13yrs	데이터 없음	0.094% $ 94.8k
Guizhong Liu	Senior Vice President of Early Drug Discovery	9.1yrs	데이터 없음	데이터 없음
Alexander Goergen	VP & Head of Business Development	7.1yrs	데이터 없음	데이터 없음
Jiping Zha	Executive Vice President of Clinical Development	3.1yrs	데이터 없음	데이터 없음
Songmao Zheng	VP and Head of Clinical & Quantitative Pharmacology	no data	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: ADAG 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter P. Luo	Co- Founder	6.8yrs	데이터 없음	3.25% $ 3.3m
Man Kin Tam	CFO & Director	3.8yrs	데이터 없음	데이터 없음
Li Zhu	Independent Director	1.3yrs	데이터 없음	데이터 없음
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	3.3yrs	데이터 없음	데이터 없음
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	3.3yrs	데이터 없음	데이터 없음
Mervyn J. Turner	Independent Director	1.6yrs	데이터 없음	데이터 없음
Cuong Viet Do	Independent Director	2yrs	데이터 없음	데이터 없음
David R. Gandara	Member Scientific & Strategic Advisory Board	2.8yrs	데이터 없음	데이터 없음
Yumeng Wang	Director	1.6yrs	데이터 없음	데이터 없음
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	1.7yrs	데이터 없음	데이터 없음
Yiu Leung Cheung	Independent Director	3.8yrs	데이터 없음	데이터 없음
Stanley Frankel	Member Scientific & Strategic Advisory Board	3.3yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: ADAG 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Adagene 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Adagene Inc. Announces Board and Management Changes

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령